exRNAdisease

General Information

Database ID:

exR0005801

RNA Name:

GNAS

RNA Type:

mRNA

Chromosome:

chr20

Starnd:

Coordinate:

Start Site(bp):

58839718

End Site(bp):

58911192

External Links:

Disease Information

Disease Name:	Down Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D004314
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Syndrome, Down//Mongolism//47,XY,+21//Trisomy G//47,XX,+21//Down's Syndrome//Downs Syndrome//Syndrome, Down's//Trisomy 21//Trisomy 21, Mitotic Nondisjunction//Down Syndrome, Partial Trisomy 21//Partial Trisomy 21 Down Syndrome//Trisomy 21, Meiotic Nondisjunction

Expression Detail

GEO ID:	GSE16176
Description:	Expression profiles of amniotic fluid from human fetuses with Down syndrome and euploid controls
Experimental Design:	Disease vs Control
Case Disease Type:	Down Syndrome
Case Disease SubType:	NA
Case Sample:	Down Syndrome
Control Sample:	Normal
Number of Case:	7
Number of Control:	7
Number of Samples:	14

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AADAT	chr4	170060222	170091699	-
AL133352.1	chr10	100505628	100529881	-
AC138811.2	chr16	18788063	18801519	-
ACLY	chr17	41866917	41930542	-
AC004922.1	chr7	99325879	99394653	+
ABRACL	chr6	139028745	139043302	+
AC012254.2	chr18	47108188	47176345	-
AGFG1	chr2	227472152	227561214	+
AKAP17A	chrX	1591604	1602520	+
AC005258.1	chr19	2269525	2341172	+
ADCY2	chr5	7396138	7830081	+
AIG1	chr6	143060496	143341058	+
ADGRL2	chr1	81306160	81992436	+
ACKR3	chr2	236567787	236582354	+
ABI1	chr10	26746593	26861087	-
ADA	chr20	44619522	44652233	-
AKT1	chr14	104769349	104795751	-
ACTN4	chr19	38647649	38731589	+
AGO3	chr1	35930718	36072500	+
AC139530.2	chr17	81703371	81720539	+
AC140504.1	chr16	15395754	15515348	+
AC245033.1	chr15	82536788	82573194	-
AHNAK	chr11	62433542	62556235	-
AC087289.3	chr17	75898645	75930129	-
ADCY1	chr7	45574140	45723116	+
ABHD17C	chr15	80679684	80755621	+
AL136531.2	chr20	1317571	1393096	-
ALDH9A1	chr1	165662216	165698863	-
AC092647.5	chr7	55887277	55955239	+
AC010422.3	chr19	12643831	12648397	-

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-20a-5p	chr13	91351072	91351094	+
hsa-miR-103a-3p	chr5	168560904	168560926	-
hsa-miR-146a-5p	chr5	160485372	160485393	+
hsa-miR-1181	chr19	10403505	10403525	-

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC007637.1	chr12	109111218	109125594	+
AC007952.4	chr17	19112000	19112636	-
AC010442.1	chr5	466124	473098	-
AC010642.2	chr19	58309727	58327248	-
AC011447.3	chr19	20122569	20321305	-
AC016876.2	chr17	7581964	7584086	-
AC023509.1	chr12	53441741	53467528	+
AC040162.3	chr16	67882461	67886367	+
AC090587.2	chr11	3854612	3855399	+
AC106864.1	chr4	112693047	112706810	-
AC124068.2	chr15	89335053	89336161	+
AC132217.1	chr11	2129121	2129964	-
AL022311.1	chr22	37876148	37895563	+

Display:

Experiment Detail

GEO ID:	GSE16176
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	NA
RNA Extract protocol:	RNA was extracted from 10 mL AF with 30 mL TRIzol LS Reagent (Invitrogen, Carlsbad, CA) and 8 mL chloroform. After RNA extraction, RNA was purified and DNA was removed using the RNeasy® Maxi Kit, including the DNase step according to the manufacturer's protocol (QIAGEN, Valencia, CA). RNA was precipitated using 3M NaOAc and 100% ethanol, and 80% ethanol was added after 4 hours incubation at -20 °C. cDNA, synthesized from extracted RNA, was amplified and purified using the WT-Ovation™ Pico RNA Amplification System (NuGEN, San Carlos, CA) and the DNA Clean & Concentrator™-25 (Zymo Research, Orange, CA).
RNA library preparation protocol:	biotin Samples were labeled using the FL-Ovation™ cDNA Biotin Module V2 (NuGEN, San Carlos, CA).

Reference

PMID:	19474297
Title:	Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses
Author:	Slonim DK, Koide K, Johnson KL, Tantravahi U, Cowan JM, Jarrah Z, Bianchi DW
Journal:	Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9425-9.
Description:	To characterize the differences between second trimester Down syndrome (DS) and euploid fetuses, we used Affymetrix microarrays to compare gene expression in uncultured amniotic fluid supernatant samples.